Effects of aclidinium oral inhalation: A Synthesis of Findings from 3 Studies

  1. Home
  2. Effects of aclidinium oral inhalation
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of aclidinium oral inhalation: A Synthesis of Findings from 3 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of aclidinium oral inhalation: A Synthesis of Findings from 3 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Several studies have shown that aclidinium bromide oral inhalation powder is effective for the maintenance treatment of chronic obstructive pulmonary disease (COPD). 2 reports that aclidinium is a novel, long-acting muscarinic antagonist indicated for the maintenance treatment of COPD. A Phase III study 3 evaluated the efficacy and safety of twice-daily aclidinium 200 μg and 400 μg versus placebo in the treatment of moderate-to-severe COPD and found that it was significantly effective and safe compared to placebo. These studies suggest that aclidinium inhalation may improve symptoms and quality of life in COPD patients.

Benefits and Risks

Benefit Summary

Aclidinium inhalation may improve symptoms and quality of life in COPD patients. 2 and 3 show the efficacy and safety of aclidinium.

Risk Summary

These studies do not specifically mention the risks of aclidinium inhalation. However, risks common to all medications, such as side effects and allergic reactions, should be considered.

Comparison Between Studies

Commonalities

All of these studies suggest that aclidinium inhalation may be effective for COPD patients.

Differences

2 focuses on the long-term safety and efficacy of aclidinium, while 3 assesses efficacy and safety over a 12-week treatment period.

Consistency and Contradictions of Results

The results of these studies suggest that aclidinium inhalation is effective for COPD patients and there are no contradictions.

Notes on Real-Life Application

It is important to use aclidinium inhalation as directed by a doctor. It is also necessary to be aware of potential risks such as side effects and allergic reactions.

Limitations of Current Research

These studies evaluate the effectiveness of aclidinium inhalation. Further research is needed to compare it with other therapies and investigate long-term effects.

Future Research Directions

Further research is needed on the long-term efficacy and safety of aclidinium inhalation, comparison with other treatments, and effectiveness in different COPD severity levels.

Conclusion

Aclidinium inhalation is a potential treatment option for improving symptoms in COPD patients. However, further research is needed, and it is essential to use this medication as directed by a doctor.

Literature analysis of 3 papers
Positive Content
3
Neutral Content
0
Negative Content
0
Article Type
3
0
0
0
3
1.

A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.

Author: KhaliliehSauzanne G, YeeKa Lai, FanLi, LiuRachael, HeberWalter, DunzoElise, TriantafyllouIlias, HussainiAzra, IwamotoMarian

HIV treatment
QTc prolongation

Doravirine, a novel HIV-1 non-nucleoside reverse transcriptase inhibitor, had no significant effects on the heart-rate corrected QT (QTc) interval in healthy adults when administered at a supratherapeutic dose.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.

Author: GelbArthur F, TashkinDonald P, MakeBarry J, ZhongXiaoyun, Garcia GilEsther, CaractaCynthia,

FEV1 improvement
Rescue medication reduction
SGRQ improvement
Constipation
Dry mouth

Aclidinium, a long-acting muscarinic antagonist, was well-tolerated and resulted in sustained improvements in lung function and health status in patients with chronic obstructive pulmonary disease (COPD) over a 1-year study.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

3.

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Author: KerwinEdward M, D'UrzoAnthony D, GelbArthur F, LakkisHassan, Garcia GilEsther, CaractaCynthia F,

Bronchodilation
COPD symptoms
Health status

Aclidinium 200 μg and 400 μg were associated with significant improvements in bronchodilation, health status, and COPD symptoms. Both doses were well tolerated.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.